Oral toxicity of targeted anticancer therapies

被引：11

作者：

Sibaud, V. ^{[1
]}

Boralevi, F. ^{[2
]}

Vigarios, E. ^{[1
]}

Fricain, J. -C. ^{[3
,4
]}

机构：

[1] Inst Univ Canc, F-31100 Toulouse, France

[2] Hop Pellegrin Enfants, Unite Dermatol Pediat, F-33076 Bordeaux, France

[3] UFR Odontol Bordeaux, Unite Med Buccodentaire, F-33076 Bordeaux, France

[4] Hop Pellegrin, Pole Odontol & Sante Buccale, F-33076 Bordeaux, France

来源：

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE | 2014年 / 141卷 / 05期

关键词：

Oral lesions; Targeted therapies; Mucositis; Aphthous-like lesions; Hyperkeratosis; Benign migratory glossitis; Osteonecrosis of the jaw; RENAL-CELL CARCINOMA; CLINICAL-PRACTICE GUIDELINES; TYROSINE KINASE INHIBITORS; CONCURRENT CETUXIMAB; MAMMALIAN TARGET; ADVERSE EVENTS; CUTANEOUS TOXICITIES; IMATINIB MESYLATE; MANAGEMENT; SUNITINIB;

D O I：

10.1016/j.annder.2014.03.009

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

While toxicity of targeted anticancer therapies on the oral mucosa seems relatively frequent in clinical practice, it has not been properly characterized to date, apart from aphthous-like lesions due to mTOR inhibitors. Herein, we report the main oral lesions associated with these new therapies, with a description of the most frequent but also the most characteristic clinical manifestations of these drugs, such as anti-EGFR-induced nnucositis, BRAF-inhibitor-associated hyperkeratosis, benign migratory glossitis and osteonecrosis of the jaw observed with angiogenesis inhibitors, as well as lesions more specifically linked with imatinib. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：354 / 363

页数：10

共 50 条

[31] Alopecia in patients treated with molecularly targeted anticancer therapies
Belum, V. R.
Marulanda, K.
Ensslin, C.
Gorcey, L.
Parikh, T.
Wu, S.
Busam, K. J.
Gerber, P. A.
Lacouture, M. E.
ANNALS OF ONCOLOGY, 2015, 26 (12) : 2496 - 2502
[32] Surgical Intervention for Paronychia Induced by Targeted Anticancer Therapies
Hanania, Hannah L.
Pacha, Omar
Heberton, Meghan
Patel, Anisha B.
DERMATOLOGIC SURGERY, 2021, 47 (06) : 775 - 779
[33] Skin moisturization for xerosis related to targeted anticancer therapies
Gisondi, Paolo
Girolomoni, Giampiero
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 73 (01) : E33 - E33
[34] Targeted Anticancer Therapies - TAT 2015 Congress minutes
Ajgal, Z.
Bellesoeur, A.
Baylot, C.
Bigenwald, C.
Brunot, A.
Carton, E.
De Guillebon, E.
De Nonneville, A.
Martin-Babau, J.
Flippot, R.
Gougis, P.
Mahjoubi, L.
Marques, N.
Larrouquere, L.
Pons, E.
Verlingue, L.
Viala, M.
Vicier, C.
Vinceneux, A.
Vozy, A.
Lavaud, P.
Ferte, C.
ONCOLOGIE, 2015, 17 (7-8) : 299 - 307
[35] Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
Gao, Bo
Yeap, Shang
Clements, Arthur
Balakrishnar, Bavanthi
Wong, Mark
Gurney, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 4017 - 4025
[36] Targeted alpha anticancer therapies: update and future prospects
Allen, Barry J.
Huang, Chen-Yu
Clarke, Raymond A.
BIOLOGICS-TARGETS & THERAPY, 2014, 8 : 255 - 267
[37] How to report toxicity associated with targeted therapies?
Cabarrou, B.
Boher, J. M.
Bogart, E.
Tresch-Bruneel, E.
Penel, N.
Ravaud, A.
Escudier, B.
Ait-Oukhatar, C. Mahier
Delord, J. P.
Roche, H.
Filleron, T.
ANNALS OF ONCOLOGY, 2016, 27 (08) : 1633 - 1638
[38] Acute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies
Kala, Jaya
Joseph, Teresa
Pirovano, Marta
Fenoglio, Roberta
Cosmai, Laura
KIDNEY360, 2024, 5 (11): : 1750 - 1762
[39] Design of cytotoxic anticancer therapies that circumvent systemic toxicity
不详
MUTAGENESIS, 2005, 20 (06) : 473 - 473
[40] Targeted RT study: results on acute toxicity of targeted therapies and radiotherapy
Konnerth, Dinah
Gaasch, Aurelie
Westphalen, Christoph Benedikt
Heinrich, Kathrin
Niyazi, Maximilian
Eze, Chukwuka
Rogowski, Paul
Marschner, Sebastian Norbert
Zinn, Annemarie
Belka, Claus
Corradini, Stefanie
Schoenecker, Stephan
RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S1858 - S1861

← 1 2 3 4 5 →